As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy

Just days after UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO, the company reported updated data Tuesday showing that UGN-101 (MitoGel) led to a 57% complete response rate among 61 evaluable patients in the Phase III OLYMPUS trial for the non-surgical treatment of low-grade upper urinary tract urothelial carcinoma. All 35 complete responders remain disease free at six months.